Nano-enhanced immunotherapy: Targeting the immunosuppressive tumor microenvironment

Area of Science:

• Immunology
• Oncology
• Nanotechnology

Background:

• The tumor microenvironment (TME) is a complex system supporting tumor formation and progression.
• TME heterogeneity influences immunotherapy responses, categorizing tumors as 'immune-cold' or 'immune-hot'.
• Key suppressive immune cells like macrophages, myeloid-derived suppressor cells, and regulatory T cells play critical roles in tumor development and metastasis.

Purpose of the Study:

• To review the role of major suppressive immune cells in the TME and tumor development.
• To examine clinical trials of immunotherapies targeting these immune cells.
• To explore the combination of drugs with nanomaterials for improved cancer treatment.

Main Methods:

• Literature review focusing on suppressive immune cells in the TME.
• Analysis of clinical trials for immunotherapies targeting immune cells.
• Investigation of nanomedicine applications in immunotherapy.

Main Results:

• Suppressing immune cells significantly influence TME formation and cancer progression.
• Nanotechnology presents strategies to mitigate immunotherapy's toxic side effects and improve targeting.
• Combining drugs with nanomaterials shows promise for enhancing therapeutic efficacy.

Conclusions:

• Understanding the interplay between immunotherapy, the immunosuppressive TME, and nanomedicine is crucial.
• Nanomedicine holds significant potential to advance conventional immunotherapy.
• Further research is needed to develop more effective nanomedicine-based cancer immunotherapies.